Ian Lyall is a Managing Editor at Proactive Investors. He specializes in finance, trading, and energy and mining, with a focus on commodities markets, mining operations, and sustainability. Ian's insights and analyses have been featured in prominent publications such as This Is Money, MSN, Daily Mail, and Southerneye-zim.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ian Lyall’s coverage spans across finance, investments, stocks, pharmaceuticals, and technology. He frequently reports on press releases and investment analysis within the healthcare & pharmaceutical industry and business & industry sectors.
To effectively reach out to Ian with a pitch, consider offering insights or data related to financial performance or market trends in these industries. If you represent a company making significant announcements in these areas or have expert perspectives on financial markets within the specified topics covered by Ian (finance, investments, stocks), he would likely be interested in your pitch.
As his focus is primarily on the UK stock market and companies operating within the UK's sphere of influence as well as international entities impacting those markets directly through major deals or acquisitions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) , a neuroscience imaging and biomarker analytics company, has confirmed its revenue guidance remains
By: Ian Lyall
Blue Origin , the space company founded by Jeff Bezos, is raising $10 billion in its first funding round from outside investors.
System1 Group PLC (AIM:SYS1), the marketing research company, has unequivocally rejected an improved, £43 million takeover approach from Brave Bison...
By: Ian Lyall
Water Tower Research has initiated coverage of Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company developing...
By: Oliver Haill, Ian Lyall
UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to report solid second-quarter results later this month, though it sees little room for the drugmaker to...
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from...
Cavendish has reiterated its 'buy' rating on Poolbeg Pharma PLC (AIM:POLB), arguing that the drug developer's first patient dosing marks the start of a...
HSBC has downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', arguing that a recent trial failure has removed the central pillar of its...
JP Morgan has placed Prudential PLC (LSE:PRU) on positive catalyst watch ahead of its first-half results, expecting reassurance on the impact of a Chinese...
Next PLC (LSE:NXT) could generate close to half its sales overseas within a decade, according to RBC Capital Markets, which raised its price target on the...
